OAE Journals Achieved Remarkable Progress in 2022 CiteScores Released by Scopus
We are delighted to announce that OAE journals have achieved remarkable progress in the recently released 2022 CiteScores. Among the seven OAE journals indexed by Scopus, four have shown extraordinary growth in their 2022 CiteScores: Cancer Drug Resistance (5.5, 3.7 in 2021), Journal of Cancer Metastasis and Treatment (3.2, 0.4 in 2021), Hepatoma Research (2.5, 0.6 in 2021), and Vessel Plus (1.5, 1.2 in 2021). The other three journals have received their first CiteScore this year: Journal of Translational Genetics and Genomics (2.1), Plastic and Aesthetic Research (1.4), and Mini-invasive Surgery (0.9).
CiteScore, a widely recognized metric launched by Elsevier, calculates the impact of a journal (indexed in Scopus) based on the number of citations received by its published documents (articles, reviews, conference papers, book chapters, and data papers) over a four-year period, divided by the total number of published documents (same types) during the same period. It provides a comprehensive overview of a journal's influence within the academic community.
Higher CiteScore values indicate greater citation impact and recognition, making this progress a significant validation of the hard work and dedication of our authors, reviewers, and editorial teams while also acknowledging OAE's commitment to delivering high-quality academic publications.
As we celebrate this achievement, OAE remains committed to our mission of disseminating scientific research and promoting scientific innovation, consistently striving for excellence in scholarly publishing. Once again, we extend our heartfelt gratitude to the Editorial Board members, authors, reviewers, and readers for their contribution to the success of OAE journals.
